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In early 2011, we reviewed the initial success of the
RAF inhibitor vemurafenib in mutant V600 BRAF
melanoma patients. It was soon evident that the
response to RAF inhibitor is heterogeneous and that
the short-term benefits are burdened by the develop-
ment of resistance. The field has progressed rapidly
with the Food and Drug Administration approval of
vemurafenib and the development of other RAF and
MEK (mitogen-activated protein kinase/extracellular
signal–regulated kinase) inhibitors. Despite these
advances, the issue of RAF inhibitor resistance remains.
Here, we review recent clinical advances in the field,
the growing number of resistance mechanisms, pre-
clinical evidence for combinatorial trials using RAF
inhibitors as the building blocks, and the new chal-
lenges that are arising.
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INTRODUCTION
The introduction of RAF inhibitors has dramatically changed
the treatment options for theB50% of melanoma patients that
harbor V600 BRAF mutations. However, as with other targeted
therapies, mechanisms of primary/intrinsic and acquired
resistance exist. We will initially review the phase 2 and
phase 3 trial results with vemurafenib and the findings with
the selective RAF inhibitor, dabrafenib, and new MEK (mito-
gen-activated protein kinase/extracellular signal–regulated
kinase (ERK) kinase) inhibitors. Second, we will outline
resistance mechanisms and elaborate on our model of com-
pensatory pathways being important in the primary response
and re-activation of the MEK-ERK1/2 pathway (Figure 1).
CLINICAL TRIALS LEAD THE WAY
The findings from the phase 1 vemurafenib trials in melanoma
were a breakthrough for the field (Flaherty et al., 2010) and
were rapidly supported by the phase 2 and phase 3 findings.
In the phase 2 trial of vemurafenib, 132 melanoma patients
were enrolled who were confirmed for BRAF V600 status but
had not previously received other drug regimens (Sosman
et al., 2012). Patients were dosed with 960 mg of vemurafenib
taken orally twice daily. The study yielded promising results
with a confirmed overall response rate of 53% and median
progression-free survival (PFS) of 6.8 months. Notably, 25% of
patients tested demonstrated a PFS of 412.9 months. The
phase 3 trial comprises 675 therapy-naive patients and directly
compared the efficacy of vemurafenib with the previous
first-line therapy, dacarbazine (Chapman et al., 2011,
2012b). Patients testing positive for a stage IIIC or IV BRAF
V600 melanoma were randomly assigned to the vemurafenib
group or the dacarbazine group. A marked difference between
overall response rates was observed: 48% for vemurafenib
versus 5% for dacarbazine. Median overall survival rates were
calculated to be 13.2 months, and 9.6 months for vemurafenib
and dacarbizine, respectively (Chapman et al., 2012b). In
addition, vemurafenib provided a median PFS of 5.3 months
compared with 1.6 months with dacarbazine.
Other selective RAF inhibitors including dabrafenib
(GSK2118436) with preference for the V600 mutant form of
BRAF have also been developed. Initial clinical data with
dabrafenib was promising (Hauschild et al., 2012) and this
RAF inhibitor was given Food and Drug Administration
approval in May 2013 for V600E BRAF-driven melanoma.
An open-labeled randomized phase 3 trial was conducted
with 250 patients randomly selected to receive either
dabrafenib (150 mg twice daily) or dacarbazine. A recent
update of this trail showed that dabrafenib elicited a median
PFS of 6.9 months compared with 2.7 months with
dacarbazine (Hauschild et al., 2013). It was also found that
dabrafinib provided an overall survival rate of 18.2 months
compared with 15.6 months with dacarbazine treatment.
Importantly in a phase 2 trial of dabrafenib, patients with
previously untreated or treated brain metastases exhibited res-
ponse rates of 22% and 31%, respectively (Long et al., 2012).
This is of note given the frequency of brain metastasis in
patients suffering from metastatic melanoma.
Next-generation MEK inhibitors with improved pharmaco-
kinetic properties have also shown promise as a treatment
option for mutant BRAF melanomas leading to the Food and
Drug Administration approval of trametinib (GSK1120212) in
May 2013 for the treatment of V600E/K BRAF melanoma. In a
phase I trial, trametinib provided 5.7 months of PFS in V600
mutant BRAF metastatic melanoma patients compared with
2.0 months in wild-type BRAF patients (Falchook et al., 2012).
In a phase 3 study of V600E/K BRAF patients, median PFS
was 4.8 months in the trametinib-treated cohort compared
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with 1.5 months with standard chemotherapy (Flaherty et al.,
2012b). Trametinib has also been tested in a larger scale
phase II study comprising two arms, a cohort of patients
having mutant BRAF melanoma progressing under BRAF inhi-
bitor treatment and a cohort with mutant BRAF having had no
previous BRAF-targeted treatments. Results show that
trametinib is quite effective against BRAF inhibitor naive
patients exhibiting a PFS of 4.0 months. However, PFS was
only 1.8 months in the cohort of patients who have been
treated previously with a selective BRAF inhibitor (Kim et al.,
2013). In the latter, BRAF inhibitor treatment was stopped
before trametinib treatment perhaps suggesting that MEK
inhibitors alone are not able to sufficiently inhibit the
ERK1/2 pathway in resistant patients.
Although it might seem counterintuitive to target the same
pathway at multiple points, evidence from the vemurafenib
alone trials indicated a need for 480% inhibition of phos-
pho-ERK1/2 for clinical effect (Bollag et al., 2010). Thus,
combinational therapies of RAF and MEK inhibitors are
currently being evaluated. A phase I/II trial of dabrafenib
and trametinib was conducted to address the safety and the
possibility of an adverse drug interaction (Flaherty et al.,
2012a). Median PFS was improved by 3.6 months in
patients receiving dabrafenib concurrently with a 2 mg day–1
dose of trametinib when compared with patients only being
treated with dabrafenib. In addition, a partial or complete
response was observed in 76% of the dual-therapy patients,
whereas a response rate of 54% was elicited in patients
receiving the dabrafenib monotherapy. The combined treat-
ment regimen is well tolerated by patients and even reduces
the risk of cutaneous squamous cell carcinoma/kerato-
acanthoma from 19% in a dabrafenib monotherapy to 2–7%
(depending on the concentration of MEK inhibitor used). In the
studies with trametinib alone, there was no induction of
keratoacanthoma (Kim et al., 2013).
IMMUNOLOGICAL EFFECTS OF RAF INHIBITORS
Although BRAF inhibitors block MEK-ERK1/2 activation
in cells possessing V600E BRAF, a paradox exists in that
RAF inhibitors cause induction of the pathway in wild-type
BRAF cells with high RAS activity (Kaplan et al., 2010).
This paradoxical ERK1/2 activation can induce cutaneous
squamous cell carcinoma/keratoacanthoma, adenomas, and
in one case leukemia (Callahan et al., 2012; Chapman et al.,
2012a; Su et al., 2012b). However, the same paradoxical
signaling has some positive effects. One example is
vemurafenib stimulation of the immune response. Koya
et al. (2012) describe that tumor-infiltrating lymphocytes
possessed higher secretion of the potent immunostimulant,
IFN-g, following vemurafenib treatment and this observation
correlated with an increased intrinsic cytotoxic ability.
Furthermore, they demonstrated an enhanced antitumor
effect against a subcutaneously implanted, mouse-derived
V600E BRAF melanoma line using vemurafenib in combi-
nation with adoptively transferred splenocytes designed to
target the melanocyte marker gp100. Vemurafenib paradoxi-
cally enhanced ERK1/2 signaling in these cells, and the
authors believe this may be the mechanism responsible for
the enhanced immune response and contribute to the overall
antitumoral effect.
The effect of ERK1/2 pathway inhibitors on the immune
system was also investigated by Boni and colleagues. This
group demonstrated that both RAF and MEK inhibitors
increased the expression of melanocyte differentiation anti-
gens on melanoma cells and that these melanocyte differen-
tiation antigens are targets for T-lymphocytes (Boni et al.,
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Figure 1. Overview of resistance mechanisms to RAF inhibitors in mutant BRAF melanoma. ERBB2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2;
ERK, extracellular signal–regulated kinase; MEK, mitogen-activated protein kinase/ERK kinase; MITF, microphthalmia-associated transcription factor; PDGFRb,
platelet-derived growth factor receptor b; PGC1a, peroxisome proliferator-activated receptor g coactivator 1a; PI3K, phosphatidylinositide
3-kinase; PTEN, phosphatase and tensin homolog.
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2010). The group further demonstrated that the pantropic
effects of the MEK inhibitors depress the efficacy of the
T-lymphocytes themselves, but importantly, that selective
RAF inhibitors are not suppressive. These data raise impor-
tant differences between RAF inhibitor alone versus MEK
inhibitor-containing treatments and suggest that selective
RAF inhibitors combined with immunotherapy may be an
efficacious approach to melanoma therapy.
A phase I trial was conducted based on some of these data
utilizing a dual treatment of vemurafenib combined with the
cytotoxic T-lymphocyte-associated antigen 4 blocking anti-
body, ipilimumab. However, this study was ended with
patients experiencing significant hepatotoxic effects, and trial
organizers needed to curtail drug exposure (Ribas et al., 2013).
Although these results were disappointing, there have been
significant other advances in the immunotherapy field utilizing
antibodies against programmed death 1 (Hamid et al., 2013;
Wolchok et al., 2013). Therefore, trials testing the combi-
nation of RAF inhibitor and anti-programmed death 1
antibodies are likely to be pursued in the future.
MECHANISMS OF RESISTANCE TO RAF INHIBITORS
As noted above, the durable benefit provided by RAF
inhibitors is limited by resistance. The mechanisms of resis-
tance fall into two broad categories. Intrinsic/primary resis-
tance is displayed by approximately 50% of patients—B15%
of patients show no tumor shrinkage in response to vemur-
afenib, whereas B35% of patients achieve a degree of tumor
shrinkage that is not sufficient to meet the RECIST criteria for a
partial response (Flaherty et al., 2010; Chapman et al., 2011;
Sosman et al., 2012). The other 50% of the patients initially
respond (430% tumor shrinkage) to RAF inhibitor but
subsequently develop progressive disease associated with
acquired/secondary resistance to RAF inhibitor. These two
categories are not mutually exclusive because nearly all
responders have remaining disease and, thus, may display
intrinsic resistance. Here, we review the mechanisms asso-
ciated with each category.
REACTIVATION OF ERK1/2 PATHWAY ASSOCIATED
WITH ACQUIRED RESISTANCE
Multiple studies have treated mutant BRAF melanoma lines
that are susceptible to BRAF perturbation with vemurafenib for
prolonged periods in vitro until drug-resistant colonies
develop. From these studies, it is clear that numerous mecha-
nisms of resistance can develop, even from within a single-cell
line (Gowrishankar et al., 2012). A consistent theme among
these mechanisms is ERK1/2 pathway re-activation in the
presence of RAF inhibitor. Several of these mechanisms have
been validated in patient samples.
In 2010, the initial studies on RAF inhibitor resistance from
Nazarian et al. (2010) elucidated two mutually exclusive
mechanisms to negate the blockade of BRAF V600E
signaling. The first was upregulation and activation of the
receptor tyrosine kinase (RTK), platelet-derived growth factor
receptor b (PDGFRb), and the second was expression of
mutant Q61 NRAS. More recently, NRAS mutations were
discovered in 4 of 19 patient samples (Poulikakos et al., 2011),
validating NRAS mutations co-existing with BRAF V600E as a
frequent mechanism of resistance. Although NRAS is the most
frequent form of RAS that is mutated in melanoma, mutations
in the other RAS isoforms, HRAS and KRAS, occur in 1% and
2% of patients, respectively. These may also be important in
the setting of acquired resistance to RAF inhibitors, because
acquired KRAS mutations have been reported in vemurafenib-
treated A375 V600E melanoma cell line (Su et al., 2012a).
A second mechanism of resistance that relies on ERK1/2 re-
activation is alternative splicing of V600E BRAF. Poulikakos
et al. (2011) detected a 61-kDa form of V600E BRAF, which
lacked exons 4–8 (encoding the RAS-binding domain of BRAF)
from in vitro-resistant cell lines. This V600E BRAF variant
possesses a markedly higher dimerization property irrespective
of RAS status and strongly activates MEK and ERK1/2 in the
presence of vemurafenib. In addition, V600E BRAF copy
number amplification has also been implicated as a mechan-
ism of resistance. Whole-exome sequencing of 20 patients
comparing base-line melanoma with that of a RAF inhibitor
progressing tumor revealed that 20% (4 out of 20) harbored
increased V600E BRAF copy number, which ranged from
2.2- to 12.8-fold. Further profiling of the patients with
increased copy number did not identify other known mechan-
isms of vemurafenib resistance, such as acquired NRAS
mutation or RTK amplification, raising the possibility that
V600E BRAF amplification alone is sufficient for BRAF
inhibitor resistance (Shi et al., 2012b). In a small percentage
of cases, activating MEK1 mutations have also been
implicated as a mechanism of vemurafenib resistance.
Targeted sequencing of a cancer gene panel revealed an
activating mutation in the RAF target, MEK1 (Wagle et al.,
2011). A tumor biopsied from a patient who became resistant
to vemurafenib treatment harbored a cysteine to serine muta-
tion at codon 121 (C121S) of MEK1. The phosphorylation of
ERK1/2 in cells expressing C121S MEK1 was elevated and this
variant was permissive for growth in vemurafenib-treated
mutant BRAF cell lines. However, the significance of other
MEK1 mutations has been called into question as P124S and
I111S alterations have been detected in pre-treatment samples
and do not provide resistance to RAF inhibitors (Shi et al.,
2012a). The frequency of acquired MEK mutations is likely to
become an area of active interest as RAF/MEK inhibitor
combinations are more frequently utilized.
UPREGULATED RTK SIGNALING ASSOCIATED WITH
ACQUIRED RESISTANCE
Upregulation of RTKs has been frequently linked to resistance
to targeted inhibitors. As previously reviewed (Aplin et al.,
2011), upregulation of PDGFRb and IGF-1R expression is
found in vemurafenib-resistant melanoma cell lines evolved
in vitro and in patient tumor samples following disease pro-
gression. Further studies are starting to shed light on the
mechanisms of resistance provided by RTKs. In follow-up
work on PDGFRb, Shi and colleagues showed that the
inhibition of ERK1/2 phosphorylation by vemurafenib in
PDGFRb-resistant cells is transient with a robust rebound of
phospho-ERK1/2 within 24 hours (Shi et al., 2011). The contri-
bution of this ERK1/2 signal rebound to resistance and whether
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PDGFRb is involved in regulating this rebound signal remains
to be determined. In addition to the ERK1/2 pathway, PDGFRb
may also signal via phosphatidylinositide 3-kinase/AKT. In
support of this, Shi et al. (2011) reported increased phosphory-
lation of AKT and its downstream effector, p70S6K, in
PDGFRb-mediated resistant melanoma cells. On the basis of
these findings, the authors have proposed to use a combi-
nation of MEK inhibitor, AKT inhibitor, and mammalian target
of rapamycin complex (mTORC) inhibitor to overcome
PDGFRb-mediated resistance. Although this mechanism of
resistance depends on PDGFRb for growth, PDGFRb-
overexpressing cells are surprisingly resistant to the PDGFRb
inhibitor, imatinib. This is not due to a failure of the drug to
inhibit PDGFRb kinase activity as the phosphorylation of
PDGFRb was successfully blocked by imatinib (Shi et al.,
2011). These findings raise the possibility that PDGFRb func-
tions as a scaffold protein in addition to its kinase activity to
promote resistance.
Other studies have shed light on how vemurafenib-resistant
cells that express high PDGFRb levels evade apoptosis down-
stream of re-activation of ERK1/2 signaling. Vemurafenib
induces apoptosis through upregulation of two pro-apoptotic
BH3-only proteins, Bim-EL and Bmf (Shao and Aplin, 2010).
Studies in a subset of vemurafenib-resistant cells which display
high levels of PDGFRb show that the upregulation of Bim-EL
and Bmf is silenced (Shao and Aplin, 2012). Importantly, the
repression of these genes is largely ERK1/2 independent.
Although the mechanism for Bmf repression is not clear,
Bim-EL is silenced epigenetically. Treatment with the histone
deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic
acid), reversed the repression of Bim-EL and re-sensitized
resistant cells to vemurafenib (Shao and Aplin, 2012),
suggesting that combinational treatment of vemurafenib with
histone deacetylase inhibitors may prove useful in fighting
resistance. In vitro work done by Peter Hersey’s group has
demonstrated a strong synergism in the induction of apoptosis
when vemurafenib and histone deacetylase inhibitors are
administered to V600E mutant BRAF melanoma cells (Lai
et al., 2012). Given the importance of Bim-EL in apoptosis, it
may serve as a good maker for vemurafenib responsiveness
and resistance. Indeed, Faber et al. (2011), have shown that
Bim expression predicts responsiveness to kinase inhibitor in
treatment-naive cancers.
MECHANISMS OF PRIMARY/INTRINSIC RESISTANCE
Approximately 15% of patients treated with vemurafenib
exhibit disease progression. In cell-based assays, loss or inacti-
vation of key tumor suppressors contribute to this intrinsic
resistance to vemurafenib. Both the retinoblastoma suscept-
ibility gene (pRB) and the lipid phosphatase, phosphatase and
tensin homolog (PTEN), have been implicated in intrinsic
mutant BRAF inhibitor resistance. V600E BRAF melanoma cell
lines null for PTEN tend to be more resistant to vemurafenib
treatment compared wild-type PTEN counterparts (Paraiso
et al., 2011; Xing et al., 2012). Similar findings have been
observed in response to MEK inhibitors (Gopal et al., 2010)
and are consistent with findings that activated AKT3 is suffi-
cient to provide resistance to PLX4720-mediated apoptosis
(Shao and Aplin, 2010). This apparent decrease for BRAF
oncogene addiction in mutant PTEN tumors was also demon-
strated in the clinic. Nathanson et al. (2013) have evidence
that in V600E BRAF melanoma patients with wild-type PTEN,
dabrafenib may elicit a longer PFS when compared with
patients harboring at least one mutated allele of PTEN (32.1
weeks compared with 18.3 weeks, respectively). Although this
set of data did not reach a statistically significant difference
(P¼ 0.066), a larger sample size may confirm their findings.
Alterations in RTK signaling have been implicated in the
primary resistance setting as well as in acquired resistance.
Wilson et al. (2012) demonstrated that addition of hepatocyte
growth factor to V600E BRAF melanoma cell lines was
sufficient to confer resistance to vemurafenib through c-MET
receptor activation of ERK1/2. This resistance mechanism was
attenuated by the c-MET inhibitor, crizotinib, in vitro and in a
xenograft model. Furthermore, in patients, high serum hepato-
cyte growth factor levels before a vemurafenib treatment is
predictive of a shorter PFS and reduced overall survival
(Wilson et al., 2012). A related study examined RAF inhi-
bitor resistance as a result of co-culturing mutant BRAF mela-
noma tumor cells with stromal cells. It was found that stromal
cells producing high levels of hepatocyte growth factor
conferred the strongest resistance to vemurafenib through
activation of c-MET and downstream ERK1/2 signaling
(Straussman et al., 2012).
In addition to pre-existing primary resistance mechanisms,
tumor cells may elicit an adaptive response as an escape
mechanism. Recently, our group has demonstrated adaptive
upregulation of the stemness factor, FOXD3, in response to
vemurafenib treatment (Abel and Aplin, 2010). This drug-
induced increase in FOXD3 modifies the apoptotic response
to vemurafenib such that FOXD3 knockdown in intrinsically
resistant cells markedly enhanced vemurafenib-induced apop-
tosis (Basile et al., 2012). Conversely FOXD3 expression in
RAF inhibitor-sensitive cells provided protection (Basile et al.,
2012). One target of FOXD3 is the RTK, v-erb-b2 erythro-
blastic leukemia viral oncogene homolog 3 (ERBB3)/human
EGFR 3. Activation of ERBB3 and its signaling to AKT were
enhanced in vemurafenib-inhibited melanoma cells in vitro,
melanoma cell xenografts in mice, and in patients samples
from RAF inhibitor clinical trials (Abel et al., 2013). ERBB3
signaling was dependent on its related family member, ERBB2,
and targeting ERBB3–ERBB2 signaling either molecularly or
with lapatinib in combination with the RAF inhibitor, PLX4720,
reduced tumor burden and extended latency of tumor regrowth
in vivo versus PLX4720 alone. These results suggest that
enhanced ERBB3 signaling may serve as a mechanism of
adaptive resistance to RAF and MEK inhibitors in melanoma
and that co-targeting this pathway may enhance the clinical
efficacy and extend therapeutic duration of RAF inhibitors.
A separate study focused on RAF inhibitors causing a relief
of feedback inhibition of RTK signaling and re-setting of the
ERK1/2 pathway in a subset of mutant BRAF melanoma cells
(Lito et al., 2012). Lito et al. demonstrated an ERK1/2 activa-
tion rebound in the presence of RAF inhibitors associated with
activated RTK, specifically ERBB/human EGFR family mem-
bers. The level of reactivation is modest and/or cell line
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dependent as other studies have not detected reactivation in
mutant BRAF melanoma cells (Corcoran et al., 2012;
Montero-Conde et al., 2013). They correlate this RTK-driven
ERK rebound with an elevated Ras-GTP bound state, which
induces the formation of RAF inhibitor-resistant RAF dimers.
These RAF dimers can then stimulate MEK and ERK1/2,
irrespective of RAF inhibitor. The group also showed that
blockade of the elevated RTK signaling allowed mutant BRAF
melanoma cells to become sensitized to RAF inhibitors; how-
ever, pathways in addition to ERK1/2 are targeted in this
scenario. Nevertheless, these findings add to the growing evi-
dence for upregulated RTK signaling as an adaptive response
to RAF inhibitors. Future avenues will have to investigate what
determines the range of adaptive response and optimize co-
targeting approaches.
Adaptive responses may also impact on additional path-
ways. Haq et al. (2013) described an adaptive response
to ERK1/2 pathway suppression that leads to the upregu-
lation of mitochondrial synthesis and oxidative metabolism.
They found that when RAF inhibitors are used to suppress
mutated BRAF, the transcription factor, microphthalmia-
associated transcription factor, is upregulated, and controls
expression of the mitochondrial regulator peroxisome
proliferator-activated receptor g coactivator 1a. Peroxisome
proliferator-activated receptor g coactivator 1a was sufficient
for the observed increase in mitochondrial number and out-
put, and was associated with enhanced oxygen consumption.
The group also demonstrated that mutant BRAF cells treated
with RAF inhibitors are susceptible to mitochondrial
uncouplers suggesting that ERK1/2 suppressed melanoma
cells are addicted to oxidative phosphorylation. Indeed, this
idea was substantiated in xenograft models and ushers in a
new possibility of treatment options by combining ERK1/2
pathway inhibitors with mitochondrial uncouplers.
The notion of oxidative phosphorylation state as a marker
for intrinsic resistance was also recently explored by the
Herlyn group. They demonstrated that a small subset of
melanoma cells contain a high level of the H3K4 demethy-
lase, jumonji AT-rich interactive domain 1B, and these slow-
cycling cells are inherently more resistant to chemotherapies,
as well as targeted therapies such as vemurafenib (Roesch
et al., 2013). They correlated high jumonji AT-rich interactive
domain 1B expression with elevated levels of proteins
associated with mitochondrial respiration. Similar to Haq
et al., the Herlyn group also found that inhibition of mito-
chondrial function further sensitized cells to therapeutics. In
fact, they demonstrated that various mitochondrial blockers
ablated the formation of the slow-cycling jumonji AT-rich
interactive domain 1Bhigh sub-population, suggesting that
intrinsic drug resistance is associated with elevated oxidative
phosphorylation.
PRE-CLINICAL BASIS FOR ADDITIONAL
COMBINATORIAL STRATEGIES
The introduction of vemurafenib and dabrafenib has been a
significant breakthrough in the melanoma field; and these
inhibitors now represent the building blocks for combined
targeted therapeutic strategies. Already clinical trials combin-
ing RAF inhibitors with other targeted agents have been shown
to significantly increase PFS over RAF inhibitor monotherapy.
As the clinical field quickly progresses, so do pre-clinical
studies that form the basis for future combinations. Clinically
effective ERK1/2 inhibitors are being developed and cell lines
with an acquired MEK1 gate-keeper mutation are resistant to
MEK inhibitors but susceptible to ERK1/2 inhibitor treatment
(Hatzivassiliou et al., 2012). These data support the notion
that multiple attacks on a linear pathway will be clinically
efficacious.
Table 1. RAF/MEK and PI3K/AKT combination studies
Combination Significance Citation
MEK inhibitorþ PI3K/AKT inhibitor
PD0325901þ PI-103 (PI3K-alpha inhibitor) Synergism was found in combination treatment, which strongly induced apoptosis
in mutant BRAF/PTEN null melanoma cell lines.
Xing et al. (2012)
TrametinibþGSK2126458 RAF inhibitor-resistant A375 and YUSIT1 cells were sensitive to MEK and PI3K
inhibition.
Greger et al. (2012)
AZD6244þVIII Multiple in vitro-derived and patient-derived resistant lines were synergistically
affected by combination treatment.
Atefi et al. (2011)
GDC-0973þGDC-0941 Comparisons were made between xenograft growth rates of single agent compared
with combination treatment. An additive effect on growth inhibition was observed
when combining the inhibitors.
Choo et al. (2013)
RAF inhibitorþ PI3K/AKT inhibitor
VemurafenibþMK-2206 Dose escalation of MK-2206 with vemurafenib demonstrated a combinatorial
inhibitory effect on in vitro proliferation. The combination treatment reduced cyclin
D1 expression and upregulated p27Kip1 and Bim-EL.
Su et al. (2012a)
VemurafenibþVIII In vitro-derived and patient-derived resistant melanomas were found to be
synergistically affected by combination treatment.
Atefi et al. (2011)
Abbreviations: MEK, mitogen-activated protein kinase/extracellular signal–regulated kinase (ERK) kinase; PI3K, phosphatidylinositide 3-kinase; PTEN,
phosphatase and tensin homolog.
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Building upon the idea that RTK amplification and hyper-
activation is a major mechanism of resistance, a study by
Metzner et al. (2011) demonstrated that FGF ligands and
receptors are expressed in high levels in melanoma cells. The
group demonstrated a synergistic effect in reduced proli-
feration and enhanced apoptosis when an FGF inhibitor,
either SU5402 or PD166866, was combined with RAF inhi-
bitor. The authors postulated that a greater level of clinical
efficacy may be obtained if both the presumed tumor-specific
oncogene is targeted as well as a ‘‘universally hyperactivated’’
upstream molecule.
Several studies have examined the synergism/additive
nature of targeting the phosphatidylinositide 3-kinase/AKT
pathway in combination with either RAF or MEK inhibitors
in pre-clinical models. Although many of these studies
show promise in vitro (Table 1), their utility in patients is
often burdened by toxicity issues. Xing et al. (2012) were able
to demonstrate a synergism associated with melanoma apop-
tosis when combining a MEK inhibitor with a phosphatidyl-
inositide 3-kinase inhibitor. Furthermore, a recent phase II
study of the MEK inhibitor, selumetinib, found that a low
patient response rate is associated with high basal levels of
phosphoAKT (Catalanotti et al., 2013). This further supports
the rationale that stronger antitumoral efficacy will be
obtained when multiple pathways are targeted.
ALTERNATIVE TREATMENT APPROACHES
An alternative approach is to selective targeting of signaling
pathways and to broadly attack resistance nodes, which arise
as a result of vemurafenib treatment. Based on the observation
that several of the aforementioned resistance mechanisms are
mediated by client proteins heat shock protein 90, the Smalley
group utilized the selective heat shock protein 90 inhibitor,
XL888 (Paraiso et al., 2012). Their data demonstrate that on
XL888 treatment, various molecules known to have a role in
RAF inhibitor resistance, such as PDGFRb, IGF-1R, and CRAF,
are quickly degraded as a result of loss of heat shock protein 90
chaperone function. Ultimately, this leads to an enhanced
susceptibility to apoptosis compared with a combined treat-
ment of MEK and phosphatidylinositide 3-kinase inhibition.
More recently, the McMahon and Stuart groups demon-
strated efficacy when utilizing a ‘‘drug holiday’’ regimen in a
xenograft model (Das Thakur et al., 2013). With an on-again,
off-again BRAF inhibitor treatment regimen, they were able to
demonstrate tumor shrinkage during the periods of drug
removal after the initial tumor relapse, suggesting a drug
addiction. Over time, in the non-treated state, cells would
adapt and begin to grow, however, a second treatment wave
of BRAF inhibitor would shrink the tumor again. They
demonstrated a cyclical pattern of tumor growth/shrinkage,
which was linked to BRAF inhibitor addiction.
CONCLUSIONS
Vemurafenib is one of the first successful small molecule
inhibitors for personalized, targeted, cancer treatment; how-
ever, it will likely serve as a building block for further
improvements to treatment. New studies have highlighted
the benefits of utilizing a combined treatment regimen and it is
likely that a dual or even a cocktail of selective inhibitor
agents will emerge as the standard of melanoma care in the
near future. There is now strong evidence to support combin-
ing inhibitors in the same linear pathway or attacking multiple
deregulated proteins that primarily act in distinct signaling
pathways. It is hoped that these combinatorial approaches will
ultimately lead to a better patient outcome.
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